Ronifibrate

Ronifibrate

SCHEMBL48852

CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCCOC(=O)c1cccnc1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.59
LMNA P02545 5/20 0.54
ALDH1A1 P00352 4/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
USP2 O75604 1/20 0.53
CYP1A2 P05177 3/20 0.52
CYP3A4 P08684 2/20 0.52
TSHR P16473 2/20 0.52
ABCB11 O95342 1/20 0.52
HTR2A P28223 1/20 0.52
PMP22 Q01453 1/20 0.52
PPARA Q07869 1/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
MAPT P10636 3/20 0.52
HPGD P15428 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 1/20 0.46
THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Simfibrate SCHEMBL5808862 1.00 L3MBTL1 (0.59) L3MBTL1LMNAALDH1A1KMT2AMEN1
SCHEMBL10973734 0.96 L3MBTL1 (0.55) L3MBTL1LMNAALDH1A1KMT2AMEN1
Etofibrate SCHEMBL3122 0.96 L3MBTL1 (0.55) L3MBTL1LMNAALDH1A1KMT2AMEN1
Etofibrate SCHEMBL29801484 0.96 L3MBTL1 (0.55) L3MBTL1LMNAALDH1A1KMT2AMEN1
Etofibrate SCHEMBL8168409 0.96 L3MBTL1 (0.55) L3MBTL1LMNAALDH1A1KMT2AMEN1
Etofibrate SCHEMBL1649349 0.94 L3MBTL1 (0.54) L3MBTL1LMNAALDH1A1KMT2AMEN1
SCHEMBL2615470 0.89 L3MBTL1 (0.59) L3MBTL1LMNAALDH1A1KMT2AMEN1
Ronifibrate SCHEMBL3958602 0.88 L3MBTL1 (0.47) L3MBTL1LMNAALDH1A1KMT2AMEN1
Ronifibrate SCHEMBL8165212 0.88 L3MBTL1 (0.47) L3MBTL1LMNAALDH1A1KMT2AMEN1
SCHEMBL13284409 0.84 L3MBTL1 (0.50) L3MBTL1LMNAALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2434 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108482-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS ESCIENT PHARMACEUTICALS INC (US) 2026-04-23 US claimed
EP-4680248-A1 PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM Topelia Aust Limited (ACN 652 771 670) (AU) 2026-01-21 EP claimed
US-20250367216-A1 PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY INTERCEPT PHARMACEUTICALS INC (US) 2025-12-04 US claimed
US-20250367217-A1 PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY INTERCEPT PHARMACEUTICALS INC (US) 2025-12-04 US claimed
US-20250269005-A1 METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT TOPELIA AUST LIMITED (ACN 652 771 670) (AU) 2025-08-28 US claimed
US-12377066-B2 Treatment of diseases associated with biliary system destruction ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (FR) 2025-08-05 US claimed
US-20250009744-A1 USE OF METABOLIC REGULATORS FOR THE TREATMENT OF LIPOTOXICITY IN THE LUNGS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2025-01-09 US claimed
WO-2024187239-A1 PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM TOPELIA AUST LIMITED (ACN 652 771 670) (AU) 2024-09-19 WO claimed
US-20240300907-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS INCYTE CORPORATION 2024-09-12 US claimed
EP-4337179-A1 METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT Topelia Aust Limited (ACN 652 771 670) (AU) 2024-03-20 EP claimed
US-20030235595-A1 Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent LIPOCINE, INC. 2003-12-25 US claimed
WO-2003068186-A1 PHARMACEUTICAL FORMULATIONS AND SYSTEMS FOR IMPROVED ABSORPTION AND MULTISTAGE RELEASE OF ACTIVE AGENTS LIPOCINE, INC. (US) 2003-08-21 WO claimed
US-20030077297-A1 Pharmaceutical formulations and systems for improved absorption and multistage release of active agents LIPOCINE, INC. 2003-04-24 US claimed
WO-2003007951-A1 A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR TREATMENT OF DIABETES N-GENE RESEARCH LABORATORIES INC. (US) 2003-01-30 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
US-6211207-B1 ANTIDIABETIC AGENTS AND INSULIN SENSITIVITY ENHANCER TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-04-03 US claimed
US-6211206-B1 Pharmaceutical composition TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-04-03 US claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
US-6133293-A INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN THE MECHANISM OF ACTION; POTENT DEPRESSIVE EFFECT ON DIABETIC HYPERGLYCEMIA; 2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-10-17 US claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed